Research · Sep 3, 2026
[INSM] Insmed Thesis 2026: Brensocatib Pivotal Readout Drives Bronchiectasis Launch Cycle
Insmed Inc. (NASDAQ: INSM) FY2025 revenue ~$430-475M (+25-37%) with diluted EPS ~-$4.50 to -$3.80 reflecting continued Arikayce (amikacin liposome inhalation suspension) ~$430-465M revenue (+15-20% YoY) for nontuberculous mycobacterial lung disease (NTM-LD) plus selected post-September 2024 ASPEN Phase 3 positive readout for Brensocatib (DPP1 inhibitor) in bronchiectasis + selected post-2024 NDA submission + selected ~Q3 2025 PDUFA goal date for selected first-ever bronchiectasis approved therapy under continued President + CEO Will Lewis (~13-year tenure since 2012). Clinical-stage biopharmaceutical company focused on serious + rare pulmonary diseases. Founded 1988 in Monmouth Junction New Jersey by Lon Chubiz (~37-year heritage); selected post-1996 NASDAQ listing IPO; selected post-2018 Arikayce first FDA approval; selected post-September 2024 ASPEN Phase 3 positive readout. Headquartered in Bridgewater New Jersey; ~1,300+ employees globally with ~$430-475M revenue. Single primary product franchise structure: Arikayce ~$430-465M + Brensocatib ~$5-30M + selected various pipeline. Brensocatib bronchiectasis launch cycle: selected first-in-class dipeptidyl peptidase-1 (DPP1) inhibitor; post-September 2024 ASPEN Phase 3 positive readout (selected first-ever positive Phase 3 in bronchiectasis); post-2024 NDA submission + ~Q3 2025 PDUFA goal date; selected potential FY2025 H2 first US FDA approval; selected post-FDA approval Q4 2025-Q1 2026 commercial launch; ~$3-5B+ aggregate peak sales potential (~340,000+ US bronchiectasis patients + ~750,000 aggregate US + EU + Japan + selected various); selected various indication expansion (CRSwNP + selected various). Arikayce franchise: ~$430-465M FY2025 revenue (+15-20% YoY) for NTM-LD caused by Mycobacterium avium complex (MAC); ~$1-1.5B aggregate peak sales potential. Selected various pipeline: TPIP (treprostinil palmitil inhalation powder) for pulmonary arterial hypertension + pulmonary hypertension associated with interstitial lung disease (Phase 2/3 trials) + selected various oligonucleotide-based + selected various early-stage. President + CEO Will Lewis since 2012 (~13-year tenure); CFO Sara Bonstein; CMO Martina Flammer. Capital structure: ~$1.4-1.7B aggregate cash + investments; no dividend; no buybacks (capital priority on growth + Brensocatib commercial launch); ~$0.6-0.7B annual R&D spend; selected continued cash burn; investment-grade B2/B credit rating. FY2026 thesis: Brensocatib bronchiectasis commercial launch + Arikayce continued growth + selected various TPIP + selected various pipeline progression + selected potential FY2027 commercial inflection. Risks: Brensocatib commercial launch execution, pricing + reimbursement, selected various competitive intensity, ~$0.6-0.7B annual R&D cash burn, TPIP + selected various pipeline trial execution.